Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
BOULDER, Colo., Nov. 02, 2016 -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference and the Stifel 2016 Healthcare Conference.
Details of the two presentations are as follows:
25th Annual Credit Suisse Healthcare Conference
Date: Tuesday, November 8th
Location: The Phoenician, Arizona
Presentation Time: 4:00 PM MST
Stifel 2016 Healthcare Conference
Date: Tuesday, November 15th
Location: The Lotte New York Palace Hotel, New York
Presentation Time: 10:15 AM EST
Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event.
About Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.
Contacts: Investor Relations John Graziano 1-646-378-2942 [email protected] Media Relations Lindsay Rocco 1-862-596-1304 [email protected]
